Transgene to host KOL webinar on TG4050 15
Category: dates
Transgene Announces Upcoming Investor Meetings
Transgene announces upcoming investor meetings 15
Positive data on key clinical candidates delivered in 2022 – Promising outlook for 2023 as industry interest in therapeutic cancer vaccines and oncolytic viruses gains significant momentum
2022 full-year results and business update 15
Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023
Transgene to present multiple posters highlighting the potential of its exciting immunotherapy pipeline at AACR2023 15
Transgene Appoints John C. Bell and Pedro Romero as Key Scientific Advisors
Transgene appoints John C Bell and Pedro Romero as Key Scientific advisors 15
Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration
Transgene recieves approval to start a Phase I trial of TG6050 15
Transgene announces Financial Calendar for 2023
Transgene announces Financial Calendar for 2023 15
Transgene Announces Upcoming Investor Meetings
Transgene announces upcoming investor meetings
Transgene and BioInvent joint paper on BT-001 wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022
Transgene and BioInvent joint paper on BT-001 wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022
Transgene reports business update and Q3 2022 financial position
TRANSGENE reports business update and Q3 2022 financial position